|
Quotes & Info
|
| GB > SEC Filings for GB > Form 8-K on 5-Dec-2012 | All Recent SEC Filings |
5-Dec-2012
Change in Directors or Principal Officers, Financial Statements and Exhibits
On December 5, 2012, Greatbatch, Inc. (the "Company") issued a press release announcing the election of Rudy A. Mazzocchi to its Board of Directors (the "Board"). Mr. Mazzocchi also will serve on the Board's Technology Development & Innovation and Corporate Governance & Nominating Committees. As a Director, he will be entitled to receive remuneration in accordance with the Company's Director compensation program disclosed in the Company's most recent proxy statement dated April 20, 2012. Mr. Mazzocchis' term as Director will last until the next annual meeting of stockholders.
Mr. Mazzocchi brings over 25 years of experience in the medical device industry. He is currently Chief Executive Officer of ELENZA, Inc., a company developing the world's first electronic "AutoFocal" intraocular lens, a position he has held since 2010. From 2008 to 2010, Mr. Mazzocchi was President & Chief Executive Officer of NoraVision, Inc., a neuro-opthalmoc device company specializing in non-invasive photic neurostimulation. From 2006 to 2008, he served as Managing Director of Accuitive Medical Ventures, a venture capital fund established to finance and develop early and expansion stage medical device and technology companies. Mr. Mazzocchi also served as President & Chief Executive Officer of Image-Guided Neurologics from 1998 to 2005. Prior to that, he served in a number of management and operations roles at Microvena Corporation and Cook Critical Care.
A copy of the press release is filed as exhibit 99.1 to this report.
(d) Exhibits
99.1 Press Release dated December 5, 2012.
|
|